Clovis Oncology Names Graham as New Board of Directors Chair
10 June 2019 - - US-based biopharmaceutical company Clovis Oncology, Inc. (NASDAQ: CLVS) has appointed Ginger L. Graham as Board chair to Clovis' board of directors, following the retirement of former Board chair Dr. M. James Barrett, the company said.
Ginger L. Graham has served as a member of the company's board of directors since 2013. She is the former president and CEO of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA focused on diabetes.
Previously, Graham was Group chairman, Office of the president for Guidant Corp.
She is the former president and CEO of Two Trees Consulting, where she coached first-time CEOs of public and private companies. She has been a senior lecturer and a faculty member at the Arthur Rock Center for Entrepreneurship at Harvard Business School.
Graham serves on the boards of directors for Genomic Health, Inc. (NASDAQ: GHDX) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA).
She is also a co-founder and owner of Ginger and Baker, a food-hub and tourist destination in Fort Collins, Colorado. Graham has a Bachelor of Science, Agriculture with high honors from the University of Arkansas and a Masters in Business Administration with distinction from Harvard Business School.
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the US, Europe and additional international markets.
The company targets development programmes at specific subsets of cancer populations, and simultaneously develops, with partners, for those indications that require them, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use.
Clovis Oncology is headquartered in Boulder, Colorado, with additional office locations in the US and Europe.